Traxion Sab De Cv Ord Shs GRPOF

RE:News

[Interpolation1]

LOL ... we posted at the same time.  nice!   Great news all

Red~One wrote:
PhytoPain Pharma Announces Interview With Radio-Canada Regarding Its Development of a Prescription Marijuana Drug 22 Sep 2016 13:18 ET Marketwire Canada - NFD OTTAWA, ONTARIO--(Marketwired - Sep 22, 2016) - PhytoPain Pharma ("PPP"), a subsidiary of GrowPros Cannabis Ventures Inc. ("GrowPros" or the "Company" or "GCI") (CSE:GCI), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it gave an interview to the journalist Brigitte Bureau of Radio-Canada regarding the development of a prescription marijuana drug. Shareholders can view the interview on CBC's website at https://ici.radio-canada.ca/regions/ottawa/2016/09/21/008-marijuana-medicinale-legalisation-gouvernement-trudeau.shtml According to Dr. G. Chamberland, Chief Scientific Officer, "PPP is developing a prescription drug marijuana product for consumption via inhalation "smoking". As part of its mission of bringing botanical-based therapies to patients with chronic diseases while maintaining the characteristics and properties of natural health products but backed by the scientific research and development of Pharma industry. Over the next years, the corporation is planning to develop the evidence to support the prescription of marijuana by physicians and to seek coverage by provincial and federal insurers." "By implementing this approach, we believe that PPP is addressing the missing link that has existed for years as the major barrier of access to medical cannabis by both patients and physicians across the globe", commented Ryan Brown, Vice-President of Business Development and Director of Communications for GCI. Dr. Chamberland further commented that the company intends on submitting a Clinical Trial Application later this year (pre-CTA submitted in August 2016 as per previous news release) and when authorized by Health Canada would initiate its Phase I trial in humans later this year. "PPP001 is in its early stages of development, but based on published clinical trial data, the company is confident that it can bring this product to the market after completing the studies required by regulatory agencies", commented Dr. Chamberland. The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.